Atricure, Inc. ( (ATRC) ) has released its Q2 earnings. Here is a breakdown of the information Atricure, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AtriCure, Inc. is a leading company specializing in innovative surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management, operating primarily in the medical device industry.
In its second quarter of 2025, AtriCure reported a significant increase in worldwide revenue, reaching $136.1 million, marking a 17.1% growth year-over-year. The company also noted an improvement in net loss and a substantial rise in adjusted EBITDA, alongside successful patient enrollment in the LeAAPS trial.
Key financial highlights include a 15.7% increase in U.S. revenue, driven by strong sales in key product lines such as the AtriClip FLEX·Mini device and the cryoSPHERE MAX probe. International revenue also saw a notable rise of 23.3%, indicating robust growth across various regions. Despite a slight decrease in gross margin, the company improved its net loss per share from $0.17 to $0.13 year-over-year.
Looking ahead, AtriCure has raised its financial outlook for 2025, projecting full-year revenue between $527 million and $533 million, with an expected adjusted EBITDA of $49 million to $52 million. The company anticipates continued growth and profitability, driven by its expanding portfolio and innovative technologies.